Pharmaceutical Tablet Supply – Moxifloxacin 400 mg

The contract seeks the supply of moxifloxacin hydrochloride tablets, 400 mg, packaged in 30-count bottles, ensuring full compliance with FDA regulations, current Good Manufacturing Practices, and Defense Logistics Agency standards. The product must meet rigorous quality and documentation requirements to support military and federal healthcare needs, with all manufacturing and packaging processes adhering to federally mandated pharmaceutical protocols. The solicitation is issued as a subcontract under the Department of Defense’s Medical Supply Chain Pharm FSA, with the NAICS code 325412 specifically identifying pharmaceutical preparation manufacturing as the relevant industry classification. Responses are due by May 11, 2026, with the announcement posted on May 6, 2026, providing a brief five-day window for interested parties to submit proposals. The performance location and point of contact details are not specified, but the contract is accessible through the DIBBS platform via the provided link. All bidders must demonstrate the ability to consistently deliver drug products that meet stringent federal quality, safety, and traceability benchmarks, with no set-aside provisions indicated for small or disadvantaged businesses. The urgency of the timeline and the precise regulatory demands underscore the critical nature of this procurement for the Defense Department’s pharmaceutical supply chain.